Free cash flow generation has deteriorated, swinging from a 21.1% margin in 2024Q3 to a negative 1.5% in 2026Q1, exacerbated by a $106.1 million working capital outflow.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 |
|---|
| Cash from Operations | 607.03M | 737.65M | 734.58M | 683.9M | 619.64M | 760.8M | 546.58M | 480.94M | 441.14M | 316.26M | 298.32M | 286.36M | 251.05M | 207.14M | 207.9M | 205.28M | 169.01M | 225.04M | 279.95M | 284.25M | 164.37M | 236.7M | 184.83M | 123.77M | 133.66M | 71.3M | 33.77M | 37.57M | 37.38M |
| Operating CF Margin % | - | 18.37% | 18.14% | 16.56% | 15.58% | 21.49% | 18.69% | 18.35% | 19.47% | 17.03% | 17.74% | 21% | 19.35% | 17.77% | 18.41% | 17.97% | 14.91% | 18.71% | 20.84% | 23.1% | 15.53% | 21.09% | 24.1% | 20.17% | 24.1% | 15.31% | 11.01% | 17.13% | 19.34% |
| Operating CF Growth % | -92.87% | 0.42% | 7.41% | 10.37% | -18.55% | 39.19% | 13.65% | 9.02% | 39.48% | 6.02% | 4.18% | 14.06% | 21.2% | -0.37% | 1.27% | 21.46% | -24.9% | -19.61% | -1.51% | 72.93% | -30.56% | 28.07% | 49.34% | -7.4% | 87.47% | 111.14% | -10.12% | 0.5% | - |
| Net Income | -184.65M | -142.16M | 25.29M | 480.37M | 492.61M | 398.84M | 365.31M | 254.06M | 227.22M | 125.59M | 156.09M | 152.04M | 129.92M | 105.42M | 102.12M | 115.52M | -334.11M | 109.38M | -522.27M | 154.41M | -55.78M | 142M | 89.79M | 80.15M | 50.13M | 35.41M | 17.88M | 17.12M | 23.38M |
| Depreciation & Amortization | 350.1M | 403.31M | 361.74M | 314.12M | 303.87M | 265.54M | 234.92M | 198.09M | 161.78M | 131.16M | 126.66M | 94.88M | 96.44M | 96.64M | 81.28M | 85.23M | 93.65M | 93.55M | 91.18M | 88.92M | 85.13M | 104.64M | 48.18M | 31.12M | 25.73M | 28.58M | 18.87M | 15.64M | 10.89M |
| Stock-Based Compensation | 62.7M | 71.08M | 69.89M | 72.05M | 73.62M | 71.47M | 56.34M | 57.27M | 47.35M | 44M | 43.64M | 40.12M | 31.04M | 24.54M | 21.86M | 21.71M | 25.53M | 23.81M | 24.33M | 0 | 21.09M | 16.97M | 3.81M | 0 | 1M | 4.47M | 0 | 0 | 0 |
| Deferred Taxes | -85.67M | -75.29M | -67.43M | -50.9M | -35.88M | -24.01M | -133K | -21.89M | -9.7M | 28.25M | 1.95M | 2.69M | 7.06M | -846K | 1.31M | -8.67M | -42.34M | 15.79M | 12.67M | -9.79M | 4.04M | -37.41M | 9.08M | 8.89M | 11.26M | 17.19M | -887K | 8.63M | -3.13M |
| Other Non-Cash Items | 556.29M | 466.63M | 375.41M | -29.36M | -62.02M | 6.01M | -83.59M | -12.78M | -315K | -18.68M | 6K | -12.99M | -9.64M | 6.75M | 27.38M | 18.51M | 418.73M | 25.95M | 706.23M | 10.41M | 168.52M | 21M | 21.77M | 8.46M | 28.87M | 6.59M | -1.02M | -902K | -1.16M |
| Working Capital Changes | -93.28M | 14.08M | -30.33M | -102.38M | -152.55M | 42.94M | -26.27M | 6.18M | 14.81M | 5.94M | -30.02M | 9.62M | -3.77M | -25.36M | -26.04M | -27.01M | 7.56M | -43.45M | -32.2M | 19.21M | -58.62M | -10.5M | 12.2M | -4.86M | 16.67M | -20.93M | -9.31M | -2.92M | 7.39M |
| Change in Receivables | -229K | 35.74M | 21.61M | -33.43M | -150.57M | -26.63M | -85.63M | -8.32M | -21.2M | -48.28M | -52.78M | -16.96M | -28.09M | -19.49M | -16.27M | 7.67M | -5.64M | 21.77M | -8.53M | -18.96M | -18.96M | -9.48M | -7.26M | 0 | 11.74M | -27.5M | 0 | 0 | 0 |
| Change in Inventory | -891K | -48.78M | 16.8M | -62.3M | -78.52M | -25.16M | -18.38M | -21.4M | -13.34M | -17.84M | -4.02M | 3.36M | -2.96M | -1.57M | 785K | 3.77M | 1.99M | -4.38M | -9.67M | -12.99M | -6.47M | -5.8M | -6.36M | -5.73M | -1.65M | -3.76M | -2.34M | 133K | -1.25M |
| Change in Payables | -1.93M | 2.87M | -14.27M | -20.43M | -2.65M | 44.9M | 748K | 29.77M | -12.73M | 34K | 22.08M | 1.17M | 4.6M | -7.08M | -3.26M | 2.21M | 71K | -11.49M | 8.18M | -2.59M | -2.59M | 2.54M | -2.32M | 0 | -3.75M | 312K | 0 | 0 | 0 |
| Cash from Investing | -552.55M | -209.32M | -245.09M | -563.15M | -607.92M | -1.44B | -601.54M | -681.5M | -955M | -72.59M | -686.37M | -320.29M | -297.99M | -74.05M | -54.99M | -36.65M | 5.76M | -208.82M | -227.18M | -200.78M | -107.99M | -113.99M | -599.97M | -63.39M | -78.89M | -91.92M | -14.58M | -34.17M | -23.03M |
| Capital Expenditures | -215.74M | -219.15M | -232.97M | -318.53M | -324.73M | -228.77M | -166.56M | -140.51M | -140.05M | -82.43M | -55.29M | -63.25M | -56.92M | -39.15M | -47.53M | -49.14M | -42.86M | -80.01M | -197.08M | -227.04M | -181.75M | -95.55M | -45.34M | -32.7M | -37.54M | -36.66M | -15.56M | -12.95M | -11.91M |
| CapEx % of Revenue | 5.36% | 5.46% | 5.75% | 7.71% | 8.17% | 6.46% | 5.7% | 5.36% | 6.18% | 4.44% | 3.29% | 4.64% | 4.39% | 3.36% | 4.21% | 4.3% | 3.78% | 6.65% | 14.67% | 18.45% | 17.17% | 8.51% | 5.91% | 5.33% | 6.77% | 7.87% | 5.08% | 5.91% | 6.16% |
| Acquisitions | -403.31M | 0 | -5.48M | -194.78M | -120.12M | -1.17B | -418.63M | -515.7M | -824.87M | 47.45M | -648.48M | -247.65M | -234.27M | -29.22M | -16.86M | 0 | 2.81M | -83.35M | -69.15M | -11.58M | -30.86M | -3.4M | -571.99M | -10.84M | -42.5M | -55.27M | -6.01M | -23.05M | -11.8M |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 79.34M | 20.8M | 4.55M | -2.29M | -9.35M | 264K | -1.06M | -3.89M | -805K | -516K | 3.69M | -2.22M | -1.15M | 307K | 2.79M | 5.45M | 950K | 4.03M | 51K | 2.7M | 189.54M | 132K | 1.43M | 872K | 1.16M | -250K | 7M | 1.83M | 681K |
| Cash from Financing | -83.68M | -536.73M | -550.93M | -85.52M | -42.4M | 672.6M | 47.25M | 231.94M | 558.06M | -208.48M | 390.73M | 4.55M | 61.41M | -84.24M | -111.12M | -271.79M | -167.9M | -80.98M | -17.32M | -46.43M | 5.39M | -197.58M | 436.95M | -8.79M | 5.17M | 47.23M | 782K | -11.5M | -8.02M |
| Debt Issued (Net) | 168.06M | -121.78M | -412.19M | -75.32M | 19.79M | 669.98M | 30.59M | 233.87M | 554.02M | -135.58M | 388.03M | 75.18M | 104.38M | -11.5M | -66.23M | -2.26M | 197.84M | -36.13M | 65.46M | -64.55M | 269.46M | -203.6M | 412.5M | -10.08M | 1.03M | -71.57M | -202.96M | 337.53M | -1.1M |
| Equity Issued (Net) | -213.89M | -359.96M | -119.17M | -24.16M | -38.65M | -40.71M | -23.98M | -18.09M | -13.85M | -106.91M | 10.93M | -78.11M | -122.02M | -165.93M | -64.19M | -283.8M | -356.53M | -45.9M | -115.06M | 12.36M | -161.63M | 9.13M | 26.55M | 3.98M | 5.27M | 116.69M | 235.96M | 102.99M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.92M | -1.4M | -2.11M | -1.9M | -1.47M | -729K | 0 | 0 | 0 |
| Share Repurchases | -215.83M | -360.67M | -119.17M | -24.16M | -38.65M | -40.71M | -23.98M | -18.09M | -13.85M | -106.91M | -12.27M | -117.48M | -122.02M | -165.93M | -64.19M | -283.8M | -356.53M | -45.9M | -115.06M | -41.62M | -249.96M | -18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -37.84M | -54.98M | -19.56M | 13.96M | -23.54M | 43.32M | 40.64M | 16.15M | 17.88M | 34.01M | -8.23M | 7.48M | 79.05M | 93.19M | 19.3M | 14.27M | -9.21M | 1.05M | 32.28M | 5.76M | -102.25M | 457K | 0 | -783K | 341K | 2.84M | -32.23M | -452.02M | -6.92M |
| Net Change in Cash | -33.54M | 10.43M | -78.91M | 43.27M | -5.1M | 13.2M | -6.93M | 42.73M | 30.99M | 46.44M | -321K | -42.08M | 4.1M | 46.24M | 40.78M | -110.25M | -3.41M | -61.02M | 18.14M | 50.07M | 60.56M | -92.75M | 25.23M | 59.82M | 64.24M | 25.14M | 18.12M | -9.8M | 6.9M |
| Free Cash Flow | 391.29M | 518.49M | 501.61M | 365.37M | 294.91M | 532.03M | 380.01M | 340.42M | 301.09M | 233.83M | 243.03M | 223.11M | 194.13M | 167.99M | 160.37M | 156.14M | 126.15M | 145.03M | 82.87M | 57.21M | -17.38M | 141.15M | 139.49M | 91.06M | 96.12M | 34.64M | 18.2M | 24.62M | 25.47M |
| FCF Margin % | 9.72% | 12.91% | 12.39% | 8.85% | 7.42% | 15.03% | 13% | 12.99% | 13.29% | 12.59% | 14.45% | 16.37% | 14.96% | 14.41% | 14.2% | 13.66% | 11.13% | 12.06% | 6.17% | 4.65% | -1.64% | 12.58% | 18.19% | 14.84% | 17.33% | 7.44% | 5.94% | 11.23% | 13.18% |
| FCF Growth % | -30.53% | 3.37% | 37.29% | 23.89% | -44.57% | 40% | 11.63% | 13.06% | 28.76% | -3.78% | 8.93% | 14.93% | 15.56% | 4.75% | 2.71% | 23.77% | -13.02% | 75.02% | 44.84% | 429.24% | -112.31% | 1.19% | 53.18% | -5.26% | 177.46% | 90.31% | -26.06% | -3.35% | - |
| FCF per Share | 7.99 | 10.46 | 9.72 | 7.10 | 5.75 | 10.35 | 7.51 | 6.85 | 6.14 | 4.81 | 5.07 | 4.68 | 4.08 | 3.46 | 3.31 | 3.04 | 2.02 | 2.21 | 1.23 | 0.83 | -0.25 | 1.95 | 2.49 | 1.86 | 2.03 | 0.78 | 0.57 | 1.24 | 2.48 |
| FCF Conversion (FCF/Net Income) | -2.12x | -5.11x | 71.34x | 1.44x | 1.27x | 1.95x | 1.50x | 1.91x | 1.95x | 2.56x | 1.93x | 1.92x | 1.98x | 2.01x | 2.14x | 1.87x | -0.50x | 1.97x | -0.54x | 1.84x | -2.95x | 1.67x | 2.06x | 1.54x | 2.67x | 2.01x | -3.01x | 2.19x | 1.60x |
| Interest Paid | 26.03M | 0 | 123.45M | 132.1M | 100.75M | 70.78M | 72.46M | 67.81M | 47.54M | 27.42M | 22.76M | 11.1M | 10.2M | 12.03M | 15.14M | 22.32M | 16.14M | 14.17M | 14.19M | 20.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 56.66M | 0 | 126.06M | 90.37M | 75.91M | 75.44M | 60.06M | 54.06M | 67.6M | 60.38M | 42.87M | 24.44M | 29.7M | 19.14M | 17.03M | 29.12M | 22.07M | 27.18M | 43.16M | 38.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Biotech funding cycle sensitivity
As evidenced by the most recent quarterly data, CRL's operating cash flow to net income ratio reached a volatile -2.77, highlighting a significant disconnect between accounting profitability and the actual cash-generative capacity of the firm's core preclinical research operations during periods of heavy impairment.
The persistent gap between net income and operating cash flow suggests that reported earnings are heavily influenced by non-cash charges, likely related to goodwill or asset write-downs. Investors should interpret this divergence as a signal that headline earnings may not accurately reflect the underlying cash-generating potential of the business.
Based on reported financial statements, CRL's free cash flow margin has fluctuated wildly, swinging from a peak of 21.1% in 2024Q3 to a negative 1.5% in 2026Q1, indicating that the company's ability to convert revenue into discretionary cash is highly sensitive to operational disruptions.
This volatility suggests that the company's cost structure is not sufficiently flexible to maintain cash flow stability during revenue downturns. The inability to sustain positive free cash flow in recent periods warrants further investigation into whether this is a temporary cyclical issue or a structural shift in capital intensity.
According to historical data, CRL's capital expenditure as a percentage of revenue has averaged roughly 5.5% over the last ten quarters, reflecting the ongoing necessity of maintaining a global vivarium network and specialized laboratory infrastructure to support its preclinical service offerings.
The consistent level of capital spending suggests that a significant portion of cash is committed to maintenance rather than growth, limiting the company's flexibility. Analysts should monitor whether these expenditures are effectively replacing aging assets or if they represent an increasing burden on the company's cash flow profile.
As reported in recent filings, working capital changes have been highly erratic, with a notable $106.1 million outflow in 2026Q1, which appears to have significantly pressured the company's liquidity position and overall cash flow generation during the most recent reporting period.
These swings in working capital suggest potential inefficiencies in inventory management or delays in client collections, which are critical for a project-based business model. Investors should monitor whether these fluctuations are indicative of broader operational challenges in managing the supply chain for research models.
Based on the provided cash flow data, CRL has prioritized aggressive capital deployment through acquisitions and share repurchases, including a $405.0 million net acquisition spend in 2026Q1, despite the company's recent struggles to maintain positive net income and consistent free cash flow.
This strategy appears to favor inorganic expansion over organic deleveraging, which may increase the company's risk profile in a high-interest-rate environment. The reliance on acquisitions to drive growth warrants further investigation into the return on invested capital for these recent, potentially expensive, strategic moves.
Quick answers to the most common questions about buying CRL stock.
Charles River Laboratories International, Inc. (CRL) generated $737.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Charles River Laboratories International, Inc. (CRL) generated $518.5M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Charles River Laboratories International, Inc. (CRL) spent $219.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Charles River Laboratories International, Inc. (CRL) spent $360.7M on share repurchases. This shows the company's commitment to returning capital to its equity investors.